# A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

> **NCT04501523** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 460 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT04501523
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-03
- **Primary completion:** 2027-08
- **Final completion:** 2032-08
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501523, "A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04501523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*